[
1. Abu-Soud H.M., S.L. Hazen (2000) Nitric oxide is a physiological substrate for mammalian peroxidases. J. Biol. Chem., 275: 37524-37532.]
[
2. Ahmed H.M., M.J. Blaha, K. Nasir, J.J. Rivera, R.S. Blumenthal (2012) Effects of physical activity on cardiovascular disease. Am. J. Cardiol.,109: 288-295.10.1016/j.amjcard.2011.08.042]
[
3. Aldridge W.N. (1953) Serum esterases. I. Two types of esterase (A and B) hydrolyzing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem. J., 53: 110-117.]
[
4. Andersen C.J., M.L. Fernandez (2013) Dietary approaches to improving atheroprotective HDL functions. Food Func., 4: 1304-1313. DOI: 10.1039/c3fo60207a.10.1039/c3fo60207a]
[
5. Andrews P.C., N.I. Krinsky (1981) The reductive cleavage of myeloperoxidase in half, producing enzymatically active hemi-myeloperoxidase. J. Biol. Chem., 256: 4211-4218.]
[
6. Arunima S., T. Rajamohan (2013) Effect of virgin coconat oil enriched diet on the antioxidant status and paraoxonase 1 activity in ameliorating the oxidative stress in rats – a comparative study. Food Func., 4: 1402-1409.]
[
7. Atli M. (2013) Serum paraoxonase activity and lipid hydroperoxide levels in adult football players after three days football tournament. Afr. Health. Sci., 13: 565-570.]
[
8. Aviram M., M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C.L. Bisgaier (1999) Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med., 26: 892-904.]
[
9. Aviram M., M. Rosenblat, C.L. Bisgaier, R.S. Newton, S.L. Primo-Parmo, B.N. La Du (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest., 101: 1581-1590.]
[
10. Barter P. (2011) HDL-C: role as a risk modifier. Atherosclerosis (Suppl). 12: 267-270.10.1016/S1567-5688(11)70885-6]
[
11. Belcastro A.N., G.D. Arthur, T.A. Albisser, D.A. Raj (1996) Heart, liver, and skeletal muscle myeloperoxidase activity during exercise. J. Appl. Physiol., 80: 1331-1335.]
[
12. Blazek A., J. Rutsky, K. Osei, A. Maiseyeu, S. Rajagopalan (2013) Exercise-mediated changes in high-density lipoprotein: impact on form and function. Am. Heart J., 166: 392-400.10.1016/j.ahj.2013.05.02124016485]
[
13. Brennan M.L., M.M. Anderson, D.M. Shih, X.D. Qu, X. Wang, A.C. Metha (2001) Increased atherosclerosis in myeloperoxidase deficient mice. Clin. Invest., 107: 419-430.]
[
14. Brewis I.A., P. Brennan (2010) Proteomics technologies for the global identification and quantification of proteins. Adv. Protein. Chem. Struct. Biol., 80: 1-44.]
[
15. Cakmak A., D. Zeyrek, A. Atas, O. Erel (2010) Paraoxonase activity in athletic adolescents. Pediatr. Exerc. Sci., 22: 93-104.]
[
16. Chapman M.J., H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén, A.L. Catapano (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J., 32: 1345-1361. DOI: org/10.1093/eurheartj/ehr112.]
[
17. Chen L.Q., A. Rohatgi, C.R. Ayers, S.R. Das, A. Khera, J.D. Berry (2011) Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: the Dallas Heart Study. Atherosclerosis, 219: 833-838.10.1016/j.atherosclerosis.2011.08.029322688321917261]
[
18. Costa L.G., G. Giordano, C.E. Furlong (2011) Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem. Pharmacol., 81: 337-344. DOI: 10.1016/jbcp2010.11.008.]
[
19. Danesh J. (2012) Lipid-related markers and cardiovascular disease prediction. JAMA, 307: 2499-2506.]
[
20. de Ross N.M., E.G. Schouten, L.M. Schek, A. van Toi, M.B. Katan (2002) Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women. Metabolism, 51: 1534-1537.10.1053/meta.2002.3630512489064]
[
21. Delporte C., K.Z. Boudjeltia, C. Noyon, P.G. Furtmüller, V. Nuyens, M.C. Slomianny (2014) Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100. J. Lipid. Res., 55: 747-757.]
[
22. Farid A.S., Y. Horii (2012) Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis. Lipids Health Dis., 11: 92.]
[
23. Flock M.R., P.M. Kris-Etherton (2010) Dietary guidelines for Americans implications for cardiovascular disease. Curr. Atheroscler. Rep., 13: 499-507. DOI: 10.1007/s11883-011-0205-0.10.1007/s11883-011-0205-021874316]
[
24. Gharakhanlou R., M.E. Afzalpour, A.A. Gaeini, N. Rahnamam (2007) Effects of aerobic exercises on the serum paraoxonase 1/arylesterase activity and lipid profile in non-active healthy men. Int. J Sports Sci. Eng., 1: 105-112.]
[
25. Gordon S.M., J. Deng, L.J. Lu, W.S. Davidson (2010) Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography.
J. Proteome Re., 9: 5239-5249.]
[
26. Hafiane A., J. Genest (2015) High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk. BBA Clinical., 3: 175-188.]
[
27. Haraguchi Y., R. Toh, M. Hasokawa, H. Nakajima, T. Honjo, K. Otsui (2014) Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis, 234: 288-294.10.1016/j.atherosclerosis.2014.03.00924704632]
[
28. Hazen S.L., J.W. Heinecke (1997) 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest., 99: 2075-2081.]
[
29. Hedric C.C., K. Hassan, G.P. Hough, J.H. Yoo, S. Simzar, C.R. Quinto (2000) Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler. Thromb. Vasc. Biol., 20: 1946-1952.]
[
30. Hewing B., K.J. Moore, E.A. Fisher (2012) HDL and cardiovascular risk: time to call the plumber? Circ. Res., 111: 1117-1120.]
[
31. Huang J., H. Lee, A.M. Zivkovic, J.T. Smilowitz, N. Rivera, J. German (2014) Glycomic analysis of high density lipoprotein shows a highly sialylated particle. Proteome. Res., 13: 681-691.]
[
32. Huang Y., Z. Wu, M. Riwanto, S. Gao, B.S. Levison, X. Gu (2013) Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J. Clin. Invest., 123: 3815-3828.]
[
33. Ibero-Baraibar I., I. Abete, S. Navas-Carretero, A. Massis-Zaid, J.A. Martinez (2014) Oxidize LDL levels decreases after the consumption of ready-to-eat meals supplemented with coca extract with hypochloric diet. Nutr. Meta. Cardiovasc. Dis., 24: 416-422.]
[
34. Kameda T., R. Ohkawa, K. Yano, Y. Usami, A. Miyazaki, K. Matsuda (2015) Effects of myeloperoxidase-induced oxidation on antiatherogenic functions of high-density lipoprotein. J. Lipids. DOI: 10.1155/2015/592594.10.1155/2015/592594451684726257958]
[
35. Kaur N., A. Pandey, H. Negi, N. Shafiq, S. Reddy, H. Kaur (2014) Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression. PLoS One. DOI: 10.1371/journal.pone.0094585.10.1371/journal.pone.0094585398417124728455]
[
36. Khersonsky O., D.S. Tawfik (2005) Structure-reactivity of serum paraoxonase PON1 suggests that its native activity is lactonase. Biochemistry, 44: 6371-6382.10.1021/bi047440d15835926]
[
37. Kim D.S., A.A. Burt, J.E. Ranchalis, R.J. Richter, J.K. Marshall, K.S. Nakayama (2012) Dietary cholesterol increases paraoxonase 1 activity. J. Lipid. Res., 53: 2450-58. doi: 10.1194/jlr.PO30601.]
[
38. Kim D.S., S.K. Maden, A.A. Burt, J.E. Ranchalis, C.E. Furlong, G.P. Jarvik (2013) Dietary fatty acid intake is associated with paraoxonase 1 activity in cohort-based analysis of 1,548 subjects. Lipids Health Dis., 12: 183. DOI: 10.1186/1476-511X-12-183.10.1186/1476-511X-12-183387882524330840]
[
39. Kitchen B.J., C.J. Masters, D.J. Winzor (1973) Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase. Biochem., 135: 93-99.
40. Kontush A., M. Lhomme, M.J. Chapman (2013) Unraveling the complexities of the HDL lipidome. J. Lipid. Res., 54: 2950-2963.]
[
41. Kristensen L.P., M.R. Larsen, H. Mickley, L. Saaby, A.C. Diederichsen, J. Lambrechtsen (2014) Plasma proteome profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal protein vinculin. J. Proteomics., 101: 141-153.]
[
42. Lau D., S. Baldus (2006) Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol. Ther., 111: 16-26.]
[
43. Libby P. (2015) ALX-chemy: adding spice to the inflammatory soup of atherosclerosis. Cardiovasc. Res., 105: 3-5.]
[
44. Loued S., H. Berrougui, P. Componova, S. Ikhlef, O. Helel, A. Khalil (2013) Extra-virgin olive oil consumption reduces atherosclerosis and age-related decrease in HDL and paraoxonase 1 anti-inflammatory activities. Br. J. Nutr., 110: 1272-1284.]
[
45. Maceyka M., K.B. Harikumar, S. Milstien, S. Spiegel (2012) Sphingosine-1-phosphate signaling and its role in disease. Trends. Cell. Biol., 22: 50-60.]
[
46. Mackness M., A. Boullier, N. Hennuyer, B. Mackness, M. Hall, A. Tailleux (2000) Paraoxonase activity is reduced by a pro-athrosclerotic diet in rabbits. Biochem. Biophys. Acta., 269: 232-236.]
[
47. Mackness M.I., S.D. Hallam, T. Peard, S. Warner, C.H. Walker (1985) The separation of sheep and human serum “A”-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp. Biochem. Physiol. B., 82: 675-677.]
[
48. Mackness M.I., B. Mackness, P.N. Durrington, P.W. Connelly, R.A. Hegele (1996) Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol., 7: 69-76.]
[
49. Mahdy Ali K., A. Wonnerth, K. Huber, J. Wojta (2012) Cardiovascular disease risk reduction by raising HDL cholesterol-current therapies and future opportunities. Br. J. Pharmacol., 167: 1177-1194.]
[
50. Mangge H., K. Becker, D. Fuchs, J.M. Gostner (2014) Antioxidants, inflammation and cardiovascular disease. World. J. Cardiol., 6: 462-477.]
[
51. Mann S., C. Beedie, A. Jimenez (2014) Differential effects of aerobic exercise, resistance exercise training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med., 2: 211-21. DOI: 10.1007/s40279-013-0110-5.10.1007/s40279-013-0110-5390654724174305]
[
52. Melanson S.E., S.M. Green, M.J. Wood, T.G. Neilan, E.L. Lewandowski (2006) Elevation of myeloperoxidase in conjunction with cardiac-specific markers after marathon running. Am. J. Clin. Pathol., 126: 888-893.]
[
53. Morozov V.I., S.A. Pryatkin, M.I. Kalinski, V.A. Rogozkin (2003) Effect of exercise to exhaustion on myeloperoxidase and lysozyme release from blood neutrophils. Eur. J. Appl. Physiol., 89: 257-262]
[
54. Morozov V.I., P.V. Tsyplenkov, N.D. Golberg, M.I. Kalinski (2006) The effects of high-intensity exercise on skeletal muscle neutrophil myeloperoxidase in untrained and trained rats. Eur. J. Appl. Physiol., 97: 716-722.]
[
55. Mozaffarian D. (2016) Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: A Comprehensive Review. Circulation, 13: 187-225.10.1161/CIRCULATIONAHA.115.018585481434826746178]
[
56. Nakajima T., M. Kurano, H. Takano, H. Iida, T. Fukuda, K. Meguro (2010) Acute high-intensity exercise releases myeloperoxidase and pentraxin 3 from peripheral neutrophils in healthy subjects. Circulation, 122: Abstract 13270.]
[
57. Nalcakan G.R., S.R. Varol, F. Turgay, M. Nalcakan, M.Z. Ozkol, S.O. Karamizrak (2015) Effects of aerobic training on serum paraoxonase activity and its relationship with PON1-192 phenotypes in women. J. Sport. Health Sci., 4: 1-7.]
[
58. Natarajan P., K.K. Ray, C.P. Cannon (2010) High-density lipoprotein and coronary heart disease: current and future therapies. J. Am. Coll. Cardiol., 55: 1283-1299.]
[
59. Nauseef W.M., I. Olsson, K. Arnijots (1988) Biosynthesis and processing of myeloperoxidase – a marker for myeloid differentiation. Eur. J. Hematol., 40: 97-110.]
[
60. Navab M., S.T. Reddy, B.J. Van Lenten, G.M. Anantharamaiah, A.M. Fogelman (2009) The role of dysfunctional HDL in atherosclerosis. J. Lipid. Res., 50: S145-S149.10.1194/jlr.R800036-JLR200267472018955731]
[
61. Nichols M., N. Townsend, P. Scarborough, M. Rayner (2014) Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J., 35: 2929.]
[
62. Nussbaum C., A. Klinke, M. Adam, S. Baldus, M. Sperandio (2013) Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxid. Redox Signal., 18: 692-713.]
[
63. Otocka-Kmiecik A., M. Lewandowski, R. Stolarek, U. Szkudlarek, D. Nowak, M. Orłowska-Majdak (2010) Effect of single bout of maximal exercise on plasma antioxidant status and paraoxonase activity in young sportsmen. Redox Rep., 15: 275-281.]
[
64. Otocka-Kmiecik A., M. Lewandowski, U. Szkudlarek, D. Nowak, M. Majdak-Orłowska (2014) Aerobic training modulates the effects of exercise-induced oxidative stress on PON1 activity: a preliminary study. Sci. World J. DOI: 10.1155/2014/230271.10.1155/2014/230271421403825379522]
[
65. Pareja-Galeano H., N. Garatachea, A. Lucia (2015) Exercis as a polypill for chronic disese. Prog. Mol. Biol. Transl. Sci., 135: 497-526.]
[
66. Podrez E.A., D. Schmitt, H.F. Hoff, S.L. Hazen (1999) Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest., 103: 1547-1560.]
[
67. Précourt L.P., D. Amre, M.C. Denis, J.C. Lavoie, E. Delvin, E. Seidman (2011) The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis, 214: 20-36.10.1016/j.atherosclerosis.2010.08.07620934178]
[
68. Primo-Parmo S.L., Sorenson R.C., Teiber J., B.N. La Du (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 33: 498-507.10.1006/geno.1996.02258661009]
[
69. Razavi A.E., G. Basati, J. Varshosaz, S. Abdi (2013) Association between HDL particles size and myeloperoxidase/paraoxonase-1 (MPO/PON1) ratio in patients with acute coronary syndrome. Acta Medica Iranica, 51: 365-371.]
[
70. Reihmane D., A. Jurka, P. Tretjakovs (2012) The relationship between maximal exercise-induced increases in serum IL-6, MPO and MMP-9 concentrations. Scand. J. Immunol., 76: 188-192.]
[
71. Rezaee F., B. Casetta, J.H. Levels, D. Speijer, J.C. Meijers (2006) Proteomic analysis of high-density lipoprotein. Proteomics, 6: 721-730.10.1002/pmic.20050019116419016]
[
72. Richter B., A. Niessner, M. Penka, M. Grdić, S. Steiner, B. Strasser (2005) Endurance training reduces circulating asymmetric dimethylarginine and myeloperoxidase levels in persons at risk of coronary events. Throm. Haemost., 94: 1306-1311.]
[
73. Roberts C.K., A.K. Chen, R.J. Barnard (2007) Effect of a short-term diet and exercise intervention in youth on atherosclerotic factors. Atherosclerosis, 191: 98-106.10.1016/j.atherosclerosis.2006.09.01117054960]
[
74. Rosenson R.S., H.B. Brewer, B. Ansell, P. Barter, M.J. Chapman, J.W. Heinecke, A. Kontush, A.R. Tall, N.R. Webb (2013) Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation, 128: 1256-1267.10.1161/CIRCULATIONAHA.113.000962]
[
75. Shao B., C. Tang, A. Sinha, P.S. Mayer, G.D. Davenport, N. Brot (2014) Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ. Res., 114: 1733-1742.]
[
76. Shekhanawar M., S.M. Shekhanawar, D. Krisnaswamy, V. Indumati, D. Satishkumar, V. Vijay (2013) The role of ‘paraoxonase-1 activity’ as an antioxidant in coronary artery diseases. J. Clin. Diagn. Res., 7: 1284-1287.]
[
77. Sini S., N. Jayakumari (2013) Functionally defective high density lipoprotein is pro-oxidant: a deviation from normal atheroprotective character. Inter. J. Nutr. Food Sc., 2: 92-101.]
[
78. Sorenson R.C., S.L. Primo-Parmo, C.L. Kuo, S. Adkins, O. Lockridge, B.N. La Du (1995) Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. USA., 92: 7187-7191.]
[
79. Stancu C.S., L. Toma, A.V. Sima (2012) Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell Tissue Res., 349: 433-446.]
[
80. Tang W.H., J. Hartiala, Y. Fan, Y. Wu, A.F. Stewart, J. Erdmann (2012) Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler. Thromb. Vasc. Biol., 32: 2803-2812.]
[
81. Taylor J.K., E.P. Plaisance, A.J. Mahurin, M.L. Mestek, J. Moncada-Jimenez, P.W. Grandjean (2015) Paraoxonas response to exercise and niacin therapy in men with metabolic syndrome. Redox Rep., 20: 42-48. DOI: 10.1179/1351000214Y.0000000103.10.1179/1351000214Y.0000000103]
[
82. Tomás M., M. Sentí, F. García-Faria, J. Vila, A. Torrents, M. Covas (2000) Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol., 20: 2113-2119.]
[
83. Turgay F., A.R. Şişman, A.C. Aksu (2015) Effects of anaerobic training on paraoxonase-1 enzyme (PON1) activities of high density lipoprotein subgroups and its relationship with PON1-Q192R phenotype. J. Atheroscler. Thromb., 22: 313-326.]
[
84. Vakili L., K.D. Navab, M. Shabihkhani, N. Pourtabatabaei, S. Vazirian, Z. Barseghian (2014) Systemic inflammation, intestine, and paraoxonase-1. Adv. Exp. Med. Biol., 824: 83-88.]
[
85. Van der Veen B.S., M.P. de Winther, P. Heeringa (2009) Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid. Redox Signal., 11: 2899-937.]
[
86. Verdier C., L.O. Martinez, J. Ferriéres, M. Elbaz, A. Gennoux, B. Perret (2013) Targeting high-density lipoproteins: update on a promising therapy. Arch. Cardiovasc. Dis., 106: 601-611.]
[
87. Vickers K.C., A.T. Remaley (2014) HDL and cholesterol: life after the divorce? J. Lipid. Res., 55: 4-12.]
[
88. Villella M., A. Villela (2014) Exercise and cardiovascular disea se. Kidney Blood Press. Res., 39: 147-153. DOI: 10.1159/000355790.10.1159/000355790]
[
89. Voight B.F., G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M.K. Jensen (2012) Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet, 380: 572-580.10.1016/S0140-6736(12)60312-2]
[
90. Wang F., Y. Liu, Y. Cong, P. Li, Y. Li, Z. Yan (2015) Shift of the interconnection from the reaction system of paraoxonase 1 to the peroxidation reaction system of myeloperoxidase with HDL-C levels: a marker of atherosclerosis in patients with normal cholesterol levels. Clin. Chim. Acta, 438: 370-375.10.1016/j.cca.2014.09.02025269090]
[
91. Wieslander G., N. Fabjan, M. Vogrinčič, I. Kreft, C. Janson, U. Spetz-Nyström (2011) Eating buckwheat cookies is associated with the reduction in serum levels of myeloperoxidase and cholesterol: a double blind crossover study in day-care centre staffs. Tohoku. J. Exp. Med., 225: 123-130.10.1620/tjem.225.12321931228]
[
92. Witte I., U. Foerstermann, A. Devarajan, S.T. Reddy, S. Horke (2012) Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer. J. Lipids. DOI: 10.1155/2012/342806.10.1155/2012/342806336122822666600]
[
93. Wong N.D., H. Gransar, J. Narula, L. Shaw, J.H. Moon, R. Miranda-Peats (2009) Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc. Imaging, 2: 1093-1099.]
[
94. Wysocka A., M. Cybulski, H. Berbeć, A. Wysokiński, J. Stążka, T. Zapolski (2014) Prognostic value of paraoxonase 1 in patients undergoing coronary artery bypass grafting surgery. Med. Sci. Monit., 20: 594-600.]
[
95. Yin X., S. Subramanian, S.J. Hwang, C.J. O’Donnell, C.S. Fox, P. Courchesne (2014) Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler. Thromb. Vasc. Biol., 34: 939-945.]
[
96. Youseff H., C. Groussard, S. Lemoine-Morel, J. Pincemail, C. Jacob, E. Moussa (2015) Aerobic training suppresses exercise-induced lipid peroxidation and inflammation in overweight/obese adolescent girls. Pediatr. Exerc. Sci., 27: 67-76. DOI: 10.1123/pes.2014-0008.10.1123/pes.2014-000825387489]
[
97. Zhu Y., X. Huang, Y. Zhang, Y. Wang, Y. Liu, R. Sun (2014) Anthocyanin supplementation improves HDL-associated paraoxonase 1 activity and enhances cholesterol efflux capacity in subjects with hypercholesterolemia. J. Clin. Endocrinol. Metab., 99: 561-569.
]
